Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.78 USD | -4.42% | -12.39% | -4.31% |
Jun. 01 | Transcript : Iovance Biotherapeutics, Inc. - Special Call | |
May. 13 | Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.31% | 2.18B | D+ | ||
-41.97% | 7.92B | A- | ||
+5.99% | 3.51B | C | ||
-21.69% | 1.97B | - | B- | |
-24.94% | 1.58B | C+ | ||
+31.45% | 1.14B | B- | ||
+26.75% | 792M | C- | ||
-9.83% | 690M | C+ | ||
-26.33% | 532M | C- | ||
+3.38% | 303M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IOVA Stock
- Ratings Iovance Biotherapeutics, Inc.